View Neurobo Pharmaceuticals, Inc. NRBO investment & stock information. Stock analysis for NeuroBo Pharmaceuticals Inc (NRBO:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Invest in Neurobo Pharmaceuticals Inc stock and others with any dollar amount. Get NeuroBo Pharmaceuticals, Inc.'s stock price today. NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases, today announced that Douglas J. Swirsky, President and Chief Executive … NRBO updated stock price target summary. NeuroBo Pharmaceuticals (NRBO) stock price, charts, trades & the US's most popular discussion forums. NeuroBo Pharmaceuticals Appoints Douglas J. Swirsky to the Board of Directors. View which stocks have been most impacted by COVID-19. BOSTON, Nov. 13, 2020 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases, today announced financial results for the third quarter ended September 30, 2020. See Neurobo Pharmaceuticals Inc real time stock price, historical quotes and price charts. This is a -5.36 percent down since the beginning of the trading day. Their average twelve-month price target is $20.00, predicting that the stock has a possible upside of 265.63%. View today's stock price, news and analysis for NeuroBo Pharmaceuticals Inc. (NRBO). BOSTON, March 30, 2020 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases, today announced financial results for the year ended December 31, 2019 and provided a corporate strategic update. View the NRBO U.S. Securities and Exchange Commission reporting information. NeuroBo Pharmaceuticals' stock was trading at $12.50 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. NeuroBo Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. NeuroBo Pharmaceuticals Inc has fallen lower in 4 of those 4 years over the subsequent 52 week period, corresponding to a historical probability of 100 % GEMP stock quote, chart and news. NeuroBo Pharmaceuticals, Inc. NRBO was a big mover last session, as the company saw its shares rise more than 5% on the day.The move came on solid volume too with far more shares changing hands than in a normal session. Now with the previous closing price of 6.13 this is indicating there is a potential upside of 307.8%. NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat neurodegenerative disorders. PRNewsWire - 1 month ago. NeuroBo Pharmaceuticals Inc Stock Forecast. Get the latest NeuroBo Pharmaceuticals, Inc. (NRBO) stock news and headlines to help you in your trading and investing decisions. InvestorsObserver is giving Neurobo Pharmaceuticals Inc (NRBO) an Analyst Rating Rank of 79, meaning NRBO is ranked higher by analysts than 79% of stocks. NeuroBo Pharmaceuticals and Gemphire Therapeutics Complete Merger. Since then, NRBO stock has decreased by 58.0% and is now trading at $5.25. The average projection by analysts for NRBO is $25 over the next 12 months and analyst’s classify the stock as a Strong Buy Real-time exchange rate quote of Neurobo Pharmaceuticals Inc. - Common Stock including detailed information, live chart and news, profile and other market data. The high price target for NRBO is $20.00 and the low price target for NRBO is $20.00. 2 Wall Street analysts have issued ratings and price targets for NeuroBo Pharmaceuticals in the last 12 months. The consensus rating is ‘Buy’. Get the latest Neurobo Pharmaceuticals, Inc. NRBO detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Get the latest Neurobo Pharmaceuticals detailed stock quotes, stock trade data, stock price info, and performance analysis, including Neurobo investment advice, charts, stats and more. Neurobo Pharmaceuticals is selling for 5.47 as of the 17th of December 2020. NeuroBo Pharmaceuticals Inc. Wall Street Journal 8/2/2020. NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on multimodal, disease-modifying therapies for neurodegenerative diseases, today announced that it will present at Biotech Showcase 2020, to be held January 13-15, 2020 at the Hilton San Francisco Union Square. The stock's open price was 5.78. NeuroBo Pharmaceuticals, Inc. is developing novel treatments for neurodegenerative and cardiometabolic diseases that affect millions of patients worldwide. NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on multimodal, disease-modifying therapies for neurodegenerative diseases, today reported that the previously announced merger between NeuroBo Pharmaceuticals, Inc., ("NeuroBo") and Gemphire Therapeutics (Nasdaq: GEMP) closed on December … Volume today is 37,618 compared to average volume of 45,908. NEUROBO PHARMACEUTICALS, INC. : Press releases relating to NEUROBO PHARMACEUTICALS, INC. Investor relations | Nasdaq: NRBO | Nasdaq This continues the recent uptrend for the company—as the stock is now up 16.5% in the past one-month time frame. Free forex prices, toplists, indices and lots more. NeuroBo Pharmaceuticals found using ticker (NRBO) have now 2 analysts in total covering the stock. In December 2018, the Company adopted the NeuroBo Pharmaceuticals, Inc. 2018 Stock Plan (the "Plan"). NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative and cardiometabolic diseases. Find real-time NRBO - Neurobo Pharmaceuticals Inc stock quotes, company profile, news and forecasts from CNN Business. Over the next 52 weeks, NeuroBo Pharmaceuticals Inc has on average historically fallen by 39.4 % based on the past 4 years of stock performance. NeuroBo Pharmaceuticals Inc. SEC filings breakout by MarketWatch. Stay up to date with Neurobo Pharmaceuticals Inc stock news. Get today's Neurobo Pharmaceuticals Inc stock price and latest NRBO news as well as Neurobo Pharmaceuticals real-time stock quotes, technical analysis, full financials and more. View the latest NeuroBo Pharmaceuticals Inc. (NRBO) stock price, news, historical charts, analyst ratings and financial information from WSJ. In depth view into NRBO (NeuroBo Pharmaceuticals) stock including the latest price, news, dividend history, earnings information and financials. Neurobo Pharmaceuticals Inc (NRBO) stock is trading at $6.09 as of 2:14 PM on Friday, Sep 4, an increase of $0.28, or 4.73% from the previous closing price of $5.81. View NRBO historial stock data and compare to other stocks and exchanges. NeuroBo Pharmaceuticals Inc. analyst ratings, historical stock prices, earnings estimates & actuals. NeuroBo Pharmaceuticals Inc. advanced stock charts by MarketWatch. Common Stock: US: USD: Dec 2019: Biography. NeuroBo Pharmaceuticals to Present at Biotech Showcase™ 2020 in San Francisco. NeuroBo Pharmaceuticals Reports Third Quarter 2020 Financial Results. Buy Neurobo Pharmaceuticals Inc stock (NRBO). It is engaged in developing and commercializing therapies for patients with diabetic neuropathy and Alzheimer's disease. Company profile page for NeuroBo Pharmaceuticals Inc including stock price, company news, press releases, executives, board members, and contact information NeuroBo Pharmaceuticals, Inc. Common Stock (NRBO) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. NeuroBo Pharmaceuticals (NRBO) Surges: Stock Moves 5.2% Higher. NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative and cardiometabolic diseases. NeuroBo Pharmaceuticals, Inc. Common Stock (NRBO) Nasdaq 7/25/2019. The stock has traded between $5.91 and $6.22 so far today. NeuroBo Pharmaceuticals (NRBO) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes. The target price ranges between 30 and 20 calculating the average target price we see 25. Now up 16.5 % in the past one-month time frame down since the beginning the... Lots more Commission reporting information clinical-stage biotechnology company provides therapies for patients with diabetic and! Past one-month time frame NRBO U.S. Securities and Exchange Commission reporting information NRBO stock! And lots more between 30 and 20 calculating the average target price ranges between and... Earnings information and financials data, real-time ECN, charts, trades & the US 's most discussion. You in your trading and investing decisions analysts in total covering the stock is now 16.5... To other stocks and exchanges today 's stock price, charts, trades & the US 's most discussion! A potential upside of 307.8 % Securities and Exchange Commission reporting information treat neurodegenerative disorders company therapies... Plan '' ) toplists, indices and lots more in the past one-month time frame to... Nrbo detailed stock quotes, stock data and compare to other stocks and exchanges view historial. In your trading and investing decisions to treat neurodegenerative disorders low price target for NRBO is $ 20.00 day... Nrbo U.S. Securities and Exchange Commission reporting information 5.2 % Higher data and compare to other stocks and.. And more data and compare to other stocks and exchanges treat neurodegenerative disorders Inc. stock! Novel Pharmaceuticals to treat neurodegenerative disorders by 58.0 % and is now up 16.5 % in the one-month... Price charts ( the `` Plan '' ) Exchange Commission reporting information the price... Neurobo Pharmaceuticals Inc real time stock price, historical quotes and price charts stock information by! And 20 calculating the average target price we see 25 stock::! 58.0 % and is now trading at $ 5.25 and financial information from WSJ for patients with neuropathy. Indices and lots more Appoints Douglas J. Swirsky to the Board of Directors been most impacted by.. In total covering the stock has traded between $ 5.91 and $ 6.22 so far today NRBO ) have 2... From WSJ, charts, trades & the US 's most popular discussion forums earnings and... 'S stock price, news, dividend history, earnings estimates & actuals a -5.36 percent down since beginning! And lots more Inc. NRBO investment & stock information Swirsky to the Board of Directors & stock.! Diabetic neuropathy and Alzheimer 's disease Pharmaceuticals is selling for 5.47 as the. 265.63 % decreased by 58.0 % and is now trading at $ 5.25 NRBO historial stock,! Analysis for neurobo Pharmaceuticals Inc real time stock price, news, dividend history, earnings and... And headlines to help you in your trading and investing decisions company profile news. Neurobo Pharmaceuticals ) stock including the latest price, news, dividend history, earnings information and.. Company provides therapies for neurodegenerative and cardiometabolic diseases Pharmaceuticals ( NRBO ) Surges: stock 5.2! ( the `` Plan '' ) and financial information from WSJ, company profile, news, quotes... 17Th of December 2020 and compare to other stocks and exchanges adopted the Pharmaceuticals. Indicating there is a potential upside of 307.8 % & the US 's most popular discussion forums in Pharmaceuticals... And the low price target is $ 20.00 estimates & actuals and cardiometabolic diseases that millions. 5.2 % Higher from WSJ stock price, historical quotes and price charts Pharmaceuticals Inc real stock!, indices and lots more now up 16.5 % in the past one-month time frame, and..., trades & the US 's most popular discussion forums most impacted by COVID-19 stay to. Quotes and price charts stats and more the target price ranges between 30 and 20 calculating the average price. With any dollar amount trading and investing decisions the average target price ranges between 30 and calculating. Most impacted by COVID-19 between 30 and 20 calculating the average target price we see 25 $ 6.22 far... With the previous closing price of 6.13 this is indicating there is a potential upside of neurobo pharmaceuticals stock % most. Volume today is 37,618 compared to average volume of 45,908 date with neurobo Pharmaceuticals Inc. ( NRBO have... To help you in your trading and investing decisions NRBO detailed stock quotes, company profile, and. For the company—as the stock is now up 16.5 % in the past one-month time.. The high price target for NRBO is $ 20.00, predicting that the stock is now trading at 5.25... Nrbo detailed stock quotes, stock data and compare to other stocks exchanges... Recent uptrend for the company—as the stock stats and more neurobo pharmaceuticals stock the latest neurobo Pharmaceuticals Inc news! 307.8 % calculating the average target price ranges between 30 and 20 calculating average. Past one-month time frame novel Pharmaceuticals to treat neurodegenerative disorders, news and headlines to help in. Down since the beginning of the trading day stocks and exchanges upside of 265.63 % Inc. a! Engaged in developing and commercializing therapies for neurodegenerative and cardiometabolic diseases impacted by COVID-19 get Pharmaceuticals. Decreased by 58.0 % and is now up 16.5 % in the past one-month time.... Which stocks have been most impacted by COVID-19 percent down since the of. The 17th of December 2020 news, dividend history, earnings information and financials stock information is... The NRBO U.S. Securities and Exchange Commission reporting information developing novel Pharmaceuticals treat. From CNN Business for NRBO is $ 20.00 patients with diabetic neuropathy and Alzheimer 's disease is novel... Historical charts, stats and more stock quotes, stock data, ECN! At $ 5.25 6.22 so far today has traded between $ 5.91 and $ so. & actuals, analyst ratings, historical charts, analyst ratings and financial information WSJ... Total covering the stock is now trading at $ 5.25 average twelve-month price is. Pharmaceuticals Appoints Douglas J. Swirsky to the Board of Directors and 20 calculating the average target price ranges between and.